Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update

Enrollment Ongoing in Industry’s First Potentially Pivotal Phase 2 Allogeneic CAR T Trial, ALPHA2, in Relapsed/Refractory Large B Cell LymphomaInitiated Phase 2 EXPAND Trial to Support Licensure... | May 3, 2023

Related Keywords

Illinois ,United States ,Chicago ,American ,David Chang ,Christine Cassiano ,Allogene Allo ,Timothy Moore ,American Association Of Cancer Research ,Linkedin ,Drug Administration ,American Association For Cancer Research ,Allocart Program ,Allogene Therapeutics Inc ,Nasdaq ,American Society Of Clinical Oncology ,Enrollment Ongoing ,First Potentially Pivotal Phase ,Refractory Largeb Cell ,Support Licensure ,Lymphodepleting Agent ,American Society ,Clinical Oncology ,Annual Meeting Presentation ,Interim Phase ,Renal Cell Carcinoma ,American Association ,Cancer Research ,Annual Meeting ,Provide Proof Of Concept ,Partial Response Following ,Single Infusion ,Patients Had Previously Progressed ,Standard Therapies ,Immune Checkpoint Inhibitor ,Cell Therapy Pioneer Timothy Moore ,Chief Technical ,Cash Equivalents ,Webcast Scheduled ,Chief Executive Officer ,Annual Meeting June ,Executive Vice President ,South San Francisco ,Private Securities Litigation Reform Act ,Exclusive License ,Collaboration Agreement ,Annual Report ,Quarterly Report ,Allogene Therapeutics ,Months Ended March ,Investor Contact ,Nc Stock Exchange ,News ,Information ,Press Release ,Enrollment ,Ngoing ,N ,First ,Potentially ,Pivotal ,Hase , ,Allogeneic ,Ear ,Barge ,Fell ,Ymphomainitiated ,Xpand ,Trial ,O ,Upport Allo Us0197701065 ,